双侧肾上腺肿瘤伴皮质醇增多症:手术与保守治疗对心血管结局的影响
这项国际回顾性队列研究纳入629例双侧肾上腺肿瘤伴皮质醇增多症患者,比较手术与保守治疗对心血管结局的影响。
要点
- 手术与保守治疗的全因死亡率和心血管事件率无显著差异。
- 双侧肾上腺切除术实现完全生化缓解,非致命性肾上腺危象少,改善动脉高血压。
- MACS非特异性对症治疗与所有研究合并症恶化相关。
核心结论
- 尽管不同治疗间死亡率和心血管事件率相似,手术带来更好的生化控制和更有利的合并症结局。
研究设计与样本
- 国际回顾性队列研究,纳入30个中心(欧洲10国及新加坡、美国)的629例双侧肾上腺肿瘤患者。
- 纳入标准:肿瘤≥10 mm,地塞米松后血清皮质醇≥50 nmol/L,随访至少36个月。
- 排除ACTH依赖性皮质醇增多、ACTH依赖性结节性肾上腺增生、部分糖皮质激素抵抗综合征等。
主要发现
- 629例中105例(17%)为库欣综合征,524例(83%)为轻度自主皮质醇分泌(MACS),中位年龄62岁,426例(68%)为女性。
- 库欣综合征中85例(81%)接受手术,MACS中384例(73%)接受非特异性对症治疗。
- 两组全因死亡率均为7%(库欣综合征7/105;MACS 38/524),心血管事件率分别为12%(13/105)和16%(82/524),治疗间无实质差异。
- 吸烟是所有患者关键可干预的死亡和心血管风险因素;MACS仅对症治疗者中,地塞米松后皮质醇与死亡率增加相关。
关键数值与推荐
- 双侧肾上腺切除术实现完全生化缓解,非致命性肾上腺危象少,改善动脉高血压。
- 单侧肾上腺切除术和类固醇生成抑制剂生化结局异质,无实质合并症改善。
- MACS非特异性对症治疗与所有研究合并症恶化相关。
临床怎么用
- 治疗决策需权衡手术的生化控制获益与肾上腺功能不全风险。
- 吸烟应作为所有患者重点干预的可改变风险因素。
- MACS患者仅对症治疗时需关注合并症恶化,地塞米松后皮质醇可能有助于风险分层。
局限性
- 回顾性设计可能存在选择偏倚和混杂。
- 不同治疗组基线特征可能不均衡。
- 部分患者未达到生化缓解数据完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment for patients with bilateral adrenal tumours and cortisol excess is not standardised and poses a therapeutic dilemma. Untreated cortisol excess is associated with cardiometabolic morbidity and mortality, but bilateral adrenalectomy causes adrenal insufficiency and possibly life-threatening adrenal crises. Data on cardiovascular outcomes by treatment modality are scarce. In this study we aimed to evaluate mid-term and long-term clinical and biochemical outcomes in patients with bilateral adrenal tumours and cortisol excess by treatment strategy and diagnosis. METHODS: This retrospective, international cohort study (in 30 centres across 10 countries in Europe plus Singapore and the USA) included patients with bilateral adrenal tumours of 10 mm or larger, post-dexamethasone serum cortisol concentration of 50 nmol/L or higher, and at least 36 months of follow-up, with data collection beween Feb 2, 2024, and Jan 31, 2025. Patients were excluded if they had adrenocorticotropin hormone (ACTH)-dependent cortisol excess, ACTH-dependent nodular adrenal hyperplasia, partial glucocorticoid resistance syndrome, a diagnosis inconsistent with benign adrenocortical lesions, or received systemic oral or intravenous glucocorticoids other than replacement therapy following adrenalectomy. Primary endpoints were all-cause mortality and clinical and biochemical remission rates. Secondary endpoints were the incidence of cardiovascular events, prevalence of vascular and metabolic comorbidities, and incidence of adrenal crises. FINDINGS: Of 629 patients who were diagnosed between Jan 1, 2000, and Jan 31, 2022, 105 (17%) had Cushing's syndrome and 524 (83%) had mild autonomous cortisol secretion (MACS), median age was 62 years (IQR 54·0-68·0), and 426 (68%) were female. 85 (81%) of 105 patients with Cushing's syndrome underwent surgery, and 384 (73%) of 524 patients with MACS received non-specific symptomatic treatment (ie, never underwent adrenalectomy or received steroidogenesis inhibitors). Over a median follow-up of 6·8 years, biochemical remission was achieved in 46 (45%) of 102 patients with Cushing's syndrome and in 67 (13%) of 517 patients with MACS. In both groups, 7% of patients died (Cushing's syndrome: seven of 105; MACS: 38 of 524) and 12% (13 of 105) of patients with Cushing's syndrome and 16% (82 of 524) of those with MACS had at least one cardiovascular event, without substantial differences across treatments. Smoking emerged as key modifiable mortality and cardiovascular risk factor in all patients, and in patients with MACS who only received non-specific symptomatic therapy, post-dexamethasone cortisol was also associated with increased mortality. Bilateral adrenalectomy led to full biochemical remission, few non-fatal adrenal crises, and improved arterial hypertension. Unilateral adrenalectomy and steroidogenesis inhibitors yielded heterogeneous biochemical outcomes and no substantial comorbidity improvement. Non-specific symptomatic treatment in MACS was associated with worsening of all investigated comorbidities. INTERPRETATION: Although mortality and cardiovascular event rates were similar across treatments, surgery led to better biochemical control and more favourable comorbidity outcomes. FUNDING: None.
引用
- Nowak E, Viëtor CL, Feelders RA, et al. Effect of surgical versus conservative management on cardiovascular outcomes in patients with bilateral adrenal tumours and cortisol excess: an international, retrospective cohort study. Lancet Diabetes Endocrinol. 2026. PMID: 41579871. doi:10.1016/S2213-8587(25)00302-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。